U.S. RESEARCH ROUNDUP-Eli Lilly, Physicians Realty Trust, Welltower

Coda Octopus

15/06/2021 07:57

June 15 (Reuters) - Wall Street securities analysts revised their ratings and price targets
on several U.S.-listed companies, including Eli Lilly, Physicians Realty Trust and Welltower, on
Tuesday. 
    
    HIGHLIGHTS
     * Compania Cervecerias Unidas SA  CCU.N : JP Morgan raises to neutral from underweight
     * Eli Lilly  LLY.N : JP Morgan raises target price to $260 from $240
     * Physicians Realty Trust  DOC.N : Baird cuts to neutral from outperform
     * Welltower Inc  WELL.N : Baird raises target price to $86 from $79
    
Following is a summary of research actions on U.S. companies reported by Reuters on Tuesday.
Stock entries are in alphabetical order. 
     
     * Acuity Brands Inc  AYI.N : Baird raises target price to $196 from $190
     * Allegheny Technologies  ATI.N : JP Morgan assumes with neutral rating; PT $25 vs $10
     * Applied Genetic Technologies  AGTC.O : BTIG initiates with buy rating; target price $11
     * Arco Platform Ltd  ARCE.O : Credit Suisse cuts target price to $46 from $55
     * Ashford Hospitality Trust Inc  AHT.N : Baird raises target price to $4 from $3
     * Avrobio Inc  AVRO.O : BTIG initiates coverage with buy rating; target price $23
     * Bank of America Corp  BAC.N : Credit Suisse raises target price to $46 from $44
     * Boeing  BA.N : Berenberg raises target price to $245 from $215
     * Coca-Cola Co  KO.N : Credit Suisse raises target price to $62 from $60
     * Coda Octopus Group  CODA.O : Alliance Global Partners raises target price to $13 from $11
     * Commercial Metals Co  CMC.N : Citigroup raises price target to $34 from $30
     * Community Healthcare Trust Inc  CHCT.N : Baird raises target price to $54 from $51
     * Compania Cervecerias Unidas SA  CCU.N : JP Morgan raises target price to $20.6 from $15.5
     * Compania Cervecerias Unidas SA  CCU.N : JP Morgan raises to neutral from underweight
     * Eli Lilly  LLY.N : JP Morgan raises target price to $260 from $240
     * Forma Therapeutics Holdings  FMTX.O : Jefferies assumes with buy rating; PT $40 vs $54
     * Gcm Grosvenor Inc  GCMG.O : JP Morgan raises target price to $15 from $14.5
     * Global Medical REIT Inc  GMRE.N : Baird raises target price to $17 from $15
     * Healthpeak Properties Inc  PEAK.N : Baird raises target price to $37 from $35
     * Magenta Therapeutics  MGTA.O : BTIG initiates coverage with buy rating; target price $20
     * Ovintiv Inc  OVV.N : Citigroup raises price target to $34 from $28
     * Passage Bio Inc  PASG.O : BTIG initiates coverage with buy rating; target price $25
     * Philip Morris International  PM.N : Cowen and Company raises PT to $115 from $108
     * Physicians Realty Trust  DOC.N : Baird cuts to neutral from outperform
     * Physicians Realty Trust  DOC.N : Baird raises target price to $20 from $19
     * Prothena Corporation Plc  PRTA.O : Citigroup raises price target to $57 from $39
     * Sarepta Therapeutics  SRPT.O : BTIG initiates coverage with buy rating; target price $110
     * Selecta Biosciences  SELB.O : BTIG initiates coverage with buy rating; target price $10
     * Sio Gene Therapies  SIOX.O : BTIG initiates coverage with buy rating; target price $8
     * Taysha Gene Therapies  TSHA.O : BTIG initiates coverage with buy rating; target price $44
     * Uniqure NV  QURE.O : BTIG initiates coverage with buy rating; target price $46
     * Ventas Inc  VTR.N : Baird raises target price to $63 from $58
     * Welltower Inc  WELL.N : Baird raises target price to $86 from $79
     * Xeris Pharmaceuticals Inc  XERS.O : Piper Sandler raises target price to $12 from $11
     * Zoominfo Technologies Inc  ZI.O : RBC cuts target price to $60 from $64
    

 (Compiled by Bengaluru Newsroom)
 ((Diaries@thomsonreuters.com))